Full-Time

Procurement Category Manager

Air Freight

Posted on 11/23/2025

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Woking, UK

In Person

Category
Operations & Logistics (1)
Requirements
  • University/bachelor degree qualification is preferred.
  • A recognised qualification in procurement would be considered an asset (e.g. CIPS).
  • Extensive knowledge of Air Freight Logistics.
  • Proven experience managing Air Freight Procurement, including end to end sourcing.
  • Minimum of 5 years’ experience in Procurement.
  • Proven Category management experience.
  • Experience implementing strategies aligned with organisational goals.
  • Procurement experience on a Pan-European scale is preferable.
  • Proficiency in English is essential.
  • Travel will be required regularly across markets within the IBG as well as supplier visits.
Responsibilities
  • Leads strategic planning for regional and local categories and ensures alignment across businesses in Europe.
  • Takes strategic and long term view of category, identifies and develops innovative sources and contractual arrangements.
  • Develops category strategies and initiatives, including value engineering.
  • Provides analysis and support in relation to the setting of category spend baseline and category profile, including risk assessment.
  • Aligns category strategy with local businesses and their financial plans.
  • Supports VP Procurement for the IBG in the definition of a priority list of categories suitable for strategic sourcing initiatives, aligned with the countries & Global Indirect Category procurement.
  • Records and reports value delivery of conducted sourcing projects.
  • Leads implementation of procurement strategy and sourcing execution: participates in internal and external analysis (industry and supplier) in collaboration with in-country procurement Managers as a member of a cross functional sourcing team.
  • Aligns global, regional and local category activities.
  • Supports supplier selection and provide recommendations to VP Procurement for final decision.
  • Supports fact based negotiations with suppliers.
  • Obtains stakeholder and leadership team approvals as required eg SCP & Delegation of Authority.
  • Ensures that governance processes are followed eg SCP, Delegation of Authority, Code of Conduct.
  • Ensures that category specific operational processes and policies are in place and a compliant usage.
  • Proactively organises sessions with internal customers to identify further Total Cost of Ownership reduction and value engineering opportunities for regional categories.
  • Supports the delivery of value engineering projects in countries.
  • Establishes measures and controls for countries to ensure and track successful implementation in alignment with KPIs.
  • Supports alignment of negotiation timing and contract durations between countries to enable Best Practice Sharing and supplier leverage.
  • Actively engages in local key initiatives (aggregate demand, construct bid packages, value engineering projects and support sourcing through suppliers around the region) especially negotiations to ensure value levers are effectively played.
  • Leads contract implementation and drives contract compliance and payment terms as per agreed procurement policies: works in close collaboration with in-country procurement Managers in order to ensure local acceptance of new contracts, and extended value generation to increase customer satisfaction.
  • Coordinates contract implementation tasks with in-country procurement Managers and users.
  • Closely monitors internal customers contract compliance; defines and takes approved corrective actions to improve contract compliance.
  • Secures knowledge transfer and exchange by creating and storing project deliverables and relevant tools and templates in knowledge repositories.
  • Manages supplier relationships with key suppliers within the defined category scope: in line with defined procurement strategy, supports the classification and categorisation of suppliers, including definition of supplier evaluation and audit policies.
  • Continuously tracks supplier performance, according to defined framework.
  • Supports supplier development activities; sets up cross functional review meetings with suppliers in order to improve performance and further reduce cost.
  • Proactively organises work with suppliers under the guidance of VP Procurement to identify further value delivery projects.
  • Initiates and conducts supplier audits according to defined framework under the guidance of VP Procurement.
  • Continuously identifies potential contract improvement opportunities and re-negotiations.
  • Executes large Spot Buys: sources major unplanned ad hoc demands to keep control over high spend utilising deep sourcing and/or category expertise.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE